Fig. 3

Oncogenic (deregulated) intracellular signaling pathways in activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). The oncogenic constitutive activation of canonical nuclear factor-kappa B (NF-κB) family members in activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL), together with a blockade in terminal B cell differentiation, which is in part mediated by BCL6, represent the hallmarks of ABC-DLBCL pathogenesis [13, 16–18, 102]. The different colors that are used in the figure indicate molecules that belong to a specific pathway and/or lead to a specific outcome. Adapted from REF: [3, 70, 86, 109]. Information for this figure was gleaned from the following references: [2, 3, 12, 13, 15–20, 27, 29, 54, 60, 70, 75–81, 86, 87, 90, 91, 93, 96–100, 103, 104, 107, 109, 123, 133, 148, 160, 161, 171, 232, 233, 247–251, 254–257, 259, 271, 285, 286, 307–311, 313–317, 360–365, 367, 374, 375, 377, 380–382, 384–386, 572, 612, 620]. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine kinase, SYK spleen tyrosine kinase, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, CD40L CD40 ligand, JAK Janus kinase, IRF4 interferon-regulatory factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1, BCL10 B cell lymphoma protein 10, TLR Toll-like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein kinase Cβ, STAT3 signal transducer and activator of transcription 3, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2